Cargando…

Results from an online survey of adults with cystic fibrosis: Accessing and using life expectancy information

Cystic fibrosis (CF) is the one of the most common inherited diseases. It affects around 10,000 people in the UK, and the median survival age is 47. Recent developments making use of longitudinal patient registry data are producing more detailed and relevant information about predicted life expectan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Keogh, Ruth H., Bilton, Diana, Cosgriff, Rebecca, Kavanagh, Dominic, Rayner, Oliver, Sedgwick, Philip M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461271/ https://www.ncbi.nlm.nih.gov/pubmed/30978192 http://dx.doi.org/10.1371/journal.pone.0213639

Ejemplares similares

Data Resource Profile: The UK Cystic Fibrosis Registry
por: Taylor-Robinson, David, et al.
Publicado: (2018)

The changing demography of the cystic fibrosis population: forecasting future numbers of adults in the UK
por: Keogh, Ruth H., et al.
Publicado: (2020)

Mediation of the total effect of cystic fibrosis‐related diabetes on mortality: A UK Cystic Fibrosis Registry cohort study
por: Tanner, Kamaryn T., et al.
Publicado: (2022)

Up-to-date and projected estimates of survival for people with cystic fibrosis using baseline characteristics: A longitudinal study using UK patient registry data()
por: Keogh, Ruth H., et al.
Publicado: (2018)

Using Negative Control Outcomes and Difference-in-Differences Analysis to Estimate Treatment Effects in an Entirely Treated Cohort: The Effect of Ivacaftor in Cystic Fibrosis
por: Newsome, Simon J, et al.
Publicado: (2021)

Hyperglycemia and Death in Cystic Fibrosis–Related Diabetes
por: Adler, Amanda I., et al.
Publicado: (2011)

Diabetes as a Determinant of Mortality in Cystic Fibrosis
por: Chamnan, Parinya, et al.
Publicado: (2010)

The fungal airway microbiome in cystic fibrosis and non-cystic fibrosis bronchiectasis
por: Cuthbertson, Leah, et al.
Publicado: (2021)

Perception of first respiratory infection with Pseudomonas aeruginosa by people with cystic fibrosis and those close to them: an online qualitative study
por: Palser, Sally C, et al.
Publicado: (2016)

Real-World Outcomes Among Patients with Cystic Fibrosis Treated with Ivacaftor: 2012–2016 Experience
por: Higgins, Mark, et al.
Publicado: (2020)

Health State Utility Data in Cystic Fibrosis: A Systematic Review
por: Mohindru, Bishal, et al.
Publicado: (2019)

Treatment patterns in people with cystic fibrosis: have they changed since the introduction of ivacaftor?
por: Granger, Emily, et al.
Publicado: (2022)

A guide to interpreting estimated median age of survival in cystic fibrosis patient registry reports
por: Keogh, Ruth H., et al.
Publicado: (2018)

Relationship between pulmonary exacerbations and daily physical activity in adults with cystic fibrosis
por: Savi, Daniela, et al.
Publicado: (2015)

US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis
por: Floto, R Andres, et al.
Publicado: (2016)

Optimising inhaled mannitol for cystic fibrosis in an adult population
por: Flume, Patrick A., et al.
Publicado: (2015)

Prevalence of Nontuberculous Mycobacteria in Cystic Fibrosis Clinics, United Kingdom, 2009
por: Seddon, Paul, et al.
Publicado: (2013)

US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary
por: Floto, R Andres, et al.
Publicado: (2016)

Genetic Determinants and Epidemiology of Cystic Fibrosis–Related Diabetes: Results from a British cohort of children and adults
por: Adler, Amanda I., et al.
Publicado: (2008)

CFTR modulator therapies – Effect on life expectancy in people with cystic fibrosis
por: Balfour-Lynn, I.M., et al.
Publicado: (2022)

What to expect of the first ERS/ECFS Adult Cystic Fibrosis Conference
por: Kisseleff, Jenai, et al.
Publicado: (2023)

Clinimetric analysis of outcome measures for airway clearance in people with cystic fibrosis: a systematic review
por: Stanford, Gemma E., et al.
Publicado: (2022)

Projecting the impact of triple CFTR modulator therapy on intravenous antibiotic requirements in cystic fibrosis using patient registry data combined with treatment effects from randomised trials
por: Keogh, Ruth H, et al.
Publicado: (2022)

Deciding on cystic fibrosis carrier screening: three citizens’ juries and an online survey
por: Mosconi, Paola, et al.
Publicado: (2018)

Burkholderia cepacia complex and limited cutaneous vasculitis in patients with cystic fibrosis: a case series
por: Kayria, Muttardi, et al.
Publicado: (2017)

Pseudomonas aeruginosa adaptation and diversification in the non-cystic fibrosis bronchiectasis lung
por: Hilliam, Yasmin, et al.
Publicado: (2017)

Identifying children with Cystic Fibrosis in population-scale routinely collected data in Wales: A Retrospective Review
por: Griffiths, R, et al.
Publicado: (2020)

Phase I Studies of Acebilustat: Biomarker Response and Safety in Patients with Cystic Fibrosis
por: Elborn, JS, et al.
Publicado: (2016)

Randomised cross-over trial evaluating the short-term effects of non-invasive ventilation as an adjunct to airway clearance techniques in adults with cystic fibrosis
por: Stanford, Gemma, et al.
Publicado: (2019)

Evaluation of a five-year predicted survival model for cystic fibrosis in later time periods
por: Liou, Theodore G., et al.
Publicado: (2020)

Exploring the nature of perceived treatment burden: a study to compare treatment burden measures in adults with cystic fibrosis
por: Altabee, Rana, et al.
Publicado: (2022)

Emulated trial investigating effects of multiple treatments: estimating combined effects of mucoactive nebulisers in cystic fibrosis using registry data
por: Granger, Emily, et al.
Publicado: (2023)

Dynamic predictive probabilities to monitor rapid cystic fibrosis disease progression
por: Szczesniak, Rhonda D., et al.
Publicado: (2019)

Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial
por: Serisier, David J, et al.
Publicado: (2013)

The emerging burden of liver disease in cystic fibrosis patients: A UK nationwide study
por: Toledano, M. B., et al.
Publicado: (2019)

Flexible semiparametric joint modeling: an application to estimate individual lung function decline and risk of pulmonary exacerbations in cystic fibrosis
por: Li, Dan, et al.
Publicado: (2017)

1078. Expectations and Attitudes Toward Antimicrobial Stewardship Among Cystic Fibrosis Care Providers
por: Bullington, Wendy, et al.
Publicado: (2019)

A qualitative exploration of patients’ experiences, needs and expectations regarding online access to their primary care record
por: McMillan, Brian, et al.
Publicado: (2021)

Dynamic Prediction of Survival in Cystic Fibrosis: A Landmarking Analysis Using UK Patient Registry Data
por: Keogh, Ruth H., et al.
Publicado: (2019)

Calprotectin in Cystic Fibrosis
por: Rumman, Nisreen, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_nukbg2imo469hn0fcvrs5rdnmb